Ypsomed has entered into a collaboration with Schott and Lonza, developing wearable patch injectors for the subcutaneous self-injection of large volumes of liquid formulations.
The collaboration aims to enable pharmaceutical companies to quickly bring biopharmaceuticals in a patch injector into the clinical trial stage and to the market.
Ypsomed has entered into a collaboration with Schott and Lonza to be able to offer the YpsoDose patch injector platform, which is used for the subcutaneous self-administration of high volumes of pharmaceuticals, as an integrated product. The three partners are cooperating to develop all the necessary components and manufacturing processes.
The comprehensive solution includes a ready to use cartriQ glass cartridge from Schott as the primary packaging for the drug, the YpsoDose patch injector platform from Ypsomed, and the processes for filling, assembly and testing of the final product by Lonza drug product services.
Schott develops and supplies 10 ml ready-to-use cartriQ cartridges for the YpsoDose. These cartridges require fewer process steps during filling than conventional cartridges. Lonza Drug Product Services applies its expertise in process development, testing and characterisation and implements a filling and assembly process for YpsoDose in Stein (Switzerland) to provide short implementation times for customers.
Andreas Reisse, Head of Schott Pharmaceutical Systems, said: "With this new development, for which we have also made investments at our Swiss site, we are making it possible for us to jointly optimise processes for pharmaceutical companies. At the same time, we are creating completely new possibilities in the area of self-medication in terms of drug safety and user-friendliness. This is fully in line with our aim of always acting in the best possible way for the benefit of human health."
Prof. Dr. Hanns-Christian Mahler, Head of Lonza Drug Product Services said: "The know-how and expertise of Lonza DPS in the development, manufacturing and testing of formulations and sterile products for subcutaneous administration is the ideal basis to enable our pharmaceutical and biotech customers to develop and commercialise the YpsoDose patch injector."
The advantage of the comprehensive solution, however, is that the three partners combine their know-how and together provide all the necessary processes and components for a short time-to-market of biopharmaceuticals. "Together with strong partners, we offer a comprehensive solution for patch injectors so that our customers can bring their active substances and drugs to market as a commercialisable product in a short time and at low cost," said Ulrike Bauer, Senior Vice President Delivery Systems at Ypsomed.
